Obagi Medical and Alpha Aesthetic Partners Announce Collaboration on ALOHA Program

Obagi Medical and Alpha Aesthetic Partners have announced a collaboration centered on the Aesthetics Leadership with Obagi’s Hyaluronic Acid (ALOHA) Program, an initiative designed to generate structured real-world evidence around the use of Obagi saypha MagIQ, the company’s first FDA-approved injectable hyaluronic acid (HA) filler.¹ Alpha Aesthetic Partners was selected as a launch partner for ALOHA based on its emphasis on innovation, clinical education, operational scalability, and standardized care delivery. Founded in 2023, Alpha supports a growing national network of medical aesthetic practices and emphasizes cross-site collaboration and structured training.

"At Alpha, we're focused on building capabilities and partnerships that meaningfully support our practices," said John Wheeler, CEO of Alpha Aesthetics Partners. "What stood out about Obagi's approach was the emphasis on real-world data and a thoughtful look at how skin care and injectables can work together to drive better outcomes for patients and providers."¹

The ALOHA Program

Through the ALOHA Program, Alpha will conduct a multi-site, systematic evaluation of saypha MagIQ across its practices, creating a consistent framework for data collection related to both clinical performance and patient experience. Within ALOHA, standardized data capture across Alpha’s network will allow assessment of outcomes in varied patient populations, treatment approaches, and practice types. In addition to clinical endpoints, the program places emphasis on patient satisfaction and experiential factors, recognizing their central role in aesthetic medicine. The launch of ALOHA was announced last week.²

Advanced HA Technology

Obagi saypha MagIQ is designed with proprietary MACRO Core Technology and a high usable HA content at the time of injection, consistent gel distribution, and a predictable injection force and swelling profile. For experienced injectors, these attributes may translate into more controlled delivery, potentially smoother tissue integration, and greater predictability during and after treatment. While such claims are initially supported by regulatory data, the ALOHA program is intended to explore how these features perform across a broad range of real-world scenarios.

A Holistic Approach to Aesthetic Care

The ALOHA program also explicitly positions saypha MagIQ alongside Obagi skin care regimens, reflecting a holistic view of aesthetic treatment that many practices already employ. Participating providers will be supported with structured protocols intended to deepen patient relationships and promote consistent, high-quality outcomes. This integrated model aims to explore how combining evidence-based topical regimens with HA filler treatments may influence overall aesthetic results, patient loyalty, and practice efficiency. The companies anticipate that ALOHA will become the largest real-world evaluation of a newly launched HA injectable.

Evidence-Based Growth and Leadership

For Obagi Medical, the ALOHA Program builds on more than 3 decades in physician-dispensed skincare, historically associated with treatments for hyperpigmentation, photodamage, acne, and signs of aging. The move further expands the company’s footprint into injectable aesthetics while maintaining a focus on skin health and biology. For Alpha, participation aligns with its mission to provide best-in-class operational support and clinical training across a growing network that now spans dozens of locations in multiple states.

"Partnering with an innovative leader like Alpha underscores Obagi's commitment to launching new aesthetics solutions grounded in meaningful real-world evidence," said Drew Fine, US General Manager, Professional Channel at Obagi Medical. "The ALOHA collaboration with Alpha brings together strong clinical leadership, operational excellence, and a shared focus on elevating patient care."¹

References

1. Obagi Medical and Alpha Aesthetic Partners Announce Their Collaboration in the ALOHA Program to Drive Real-World Evidence with Obagi® saypha® MagIQ™. News release. Globe Newswire. Published January 27, 2026. Accessed January 27, 2026. https://www.benzinga.com/pressreleases/26/01/g50153650/obagi-medical-and-alpha-aesthetic-partners-announce-their-collaboration-in-the-aloha-program-to-dr

2. Obagi Medical unveils ALOHA program to launch Obagi® saypha® MagIQ™ – pioneering the largest real-world evaluation of a new hyaluronic acid filler. News release. Waldencast plc. Published January 21, 2026. Accessed January 27, 2026. https://www.globenewswire.com/news-release/2026/01/21/3222768/0/en/Obagi-Medical-Unveils-ALOHA-Program-to-Launch-Obagi-saypha-MagIQ-Pioneering-the-Largest-Real-World-Evaluation-of-a-New-Hyaluronic-Acid-Filler.html